{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-001977","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.979367+00:00","generated_at":"2026-06-07T04:02:21.896315+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"4D Molecular Therapeutics appoints Noriyuki Kasahara as Chief Scientific Officer effective Jan 2, 2024","bullets":["Noriyuki Kasahara, M.D., Ph.D., appointed CSO effective January 2, 2024.","Kasahara resigned from the Board and as Chair of the Science and Technology Committee on January 1, 2024.","Resignation not due to any disagreement with the Company or Board.","He transitions from Board member to executive officer role."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-001977","json":"https://secwatch.observer/filing/0001193125-24-001977.json","markdown":"https://secwatch.observer/filing/0001193125-24-001977.md","text":"https://secwatch.observer/filing/0001193125-24-001977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312524001977/0001193125-24-001977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312524001977/d624050d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:02:21.896315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d798f0511","claim":"Noriyuki Kasahara was appointed as Chief Scientific Officer at 4D Molecular Therapeutics, Inc..","evidence_excerpt":"Effective as of January 2, 2024, Noriyuki Kasahara, M.D., Ph.D., has been appointed by the Board of Directors (the “Board”) of 4D Molecular Therapeutics, Inc. (the “Company”) as Chief Scientific Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312524001977/0001193125-24-001977-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}